Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP02 + 5-FU/LV in advanced solid tumors
NCT02884128Phase 1Completed
- Sponsor
- PharmaEngine, Inc.
- Start
- Jan 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome injection in solid tumor, sponsored by PharmaEngine, Inc. Primary endpoints: Dose Limiting Toxicity at 3 weeks and Maximum Tolerated Dose at 3 weeks. Started Jan 2006; status: completed.
02
Drugs
irinotecan liposome injection
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02884128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02884128.